Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23735854 | 0.80 | CYP3A4 (0.35) | KDM4EALDH1A1MAPTNSD2ALOX15 | |
| SCHEMBL3978933 | 0.80 | NQO2 (0.41) | KDM4EALDH1A1MAPTNSD2HPGD | |
| SCHEMBL21017039 | 0.80 | MAPT (0.34) | KDM4EALDH1A1MAPTNSD2CCR1 | |
| SCHEMBL15910913 | 0.80 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTHSD17B10NSD2 | |
| Hydrochloric Acid SCHEMBL31601055 | 0.79 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTHSD17B10NSD2 | |
| SCHEMBL20746863 | 0.77 | KDM4E (0.33) | KDM4EALDH1A1MAPTNSD2TLR9 | |
| SCHEMBL22607357 | 0.77 | KDM4E (0.33) | KDM4EALDH1A1MAPTNSD2CCR1 | |
| SCHEMBL15345060 | 0.77 | CCR1 (0.46) | KDM4EMAPTCCR1CCR5CCR8 | |
| SCHEMBL8232892 | 0.76 | KDM4E (0.32) | KDM4EALDH1A1MAPTNSD2 | |
| SCHEMBL29003788 | 0.76 | KDM4E (0.32) | KDM4EALDH1A1MAPTNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023144559-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | AdoRx Therapeutics Limited (GB) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023133225-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133229-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023097007-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023064880-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023034811-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022006543-A1 | 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159496-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | KDM4E 3046/4885ALDH1A1 3559/4885MAPT 3414/4885 |
| US-20230167093-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | KDM4E 3046/4885ALDH1A1 3559/4885MAPT 3414/4885 |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | KDM4E 814/4885ALDH1A1 1900/4885MAPT 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.